---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-118342"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:23:20.671093+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet Q3 2024 net loss $14.6M; cash $170M; denifanstat Phase 3 start expected by end of 2024

## Summary
- Net loss of $14.6M for Q3 2024, vs $6.4M in Q3 2023; R&D expense increased to $12.7M.
- Cash, equivalents and marketable securities of $170.0M as of Sept 30, 2024; expected to fund operations through 2025.
- Denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH (F2/F3 fibrosis); Phase 3 program expected to initiate by end of 2024.
- Phase 2b FASCINATE-2 results published in The Lancet Gastroenterology & Hepatology; end-of-Phase 2 interactions completed.
- License partner Ascletis completed enrollment of 480 patients in Phase 3 acne trial in China; topline results expected Q2 2025.

## SEC filing metadata
- accession: 0001104659-24-118342
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/0001104659-24-118342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/tm2428394d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-118342
- JSON: https://secwatch.observer/filing/0001104659-24-118342.json
- Plain text: https://secwatch.observer/filing/0001104659-24-118342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.